Skip to content

Startups

BEAT Bio Therapeutics

Sectors
Health & Medicine

Launched
01/01/2012

Description

BEAT BioTherapeutics is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. BEATBio holds worldwide rights to this technology and its UW founders are recognized experts in cardiovascular biology, muscle physiology and bioengineering.

Team Members

Michael Kranda

CEO

Gregory Mahairas

President & Chief Scientific Officer

Sam Teichman

Chief Medical Officer

Gallery